<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">LARONIDASE</span><br/>(la-ron'i-dase)<br/><span class="topboxtradename">Aldurazyme<br/></span><b>Classifications:</b> <span class="classification">enzyme</span>; <span class="classification">enzyme replacement therapy</span><br/><b>Prototype: </b>Pancrelipase<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2.9 mg/5 mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Laronidase is a recombinant form of human alpha-L-iduronidase used for enzyme replacement therapy in individuals with mucopolysaccharidosis
         I (MPSI). This is an inherited lysosomal storage disease caused by deficiency of the enzyme alpha-L-iduronidase.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Laronidase has been shown to improve pulmonary function and walking capacity.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of Hurler and Hurler-Scheie forms of mucopolysaccharidosis I (MPS I); treatment of moderate to severe Scheie form
         of MPS I.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to laronidase; lactation; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Renal or hepatic dysfunction; history of allergies, asthma; hypersensitivity to drugs, especially recombinant forms; pregnancy
         (category B).
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Mucopolysaccharidosis</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IV</span> <i>&gt; 5 y,</i> 0.58 mg/kg infused over 34 h once/wk<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Pretreatment with antipyretics and/or antihistamines 60 min prior to infusion is recommended.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Determine volume of infusion based on the patient's body weight (100 mL if <img src="../images/special/lesserorequal.gif"/>20
                  kg or 250 mL if &gt;20 kg). Prepare IV infusion of 0.1% albumin (human) in NS injection as follows: 1) remove and discard
                  a volume of NS injection equal to the volume of albumin (human) to be added to the IV bag (for 100 mL infusion use 2 mL of
                  5% albumin of 0.4 mL or 25% albumin, for 250 mL infusion use 5 mL of 5% albumin or 1 mL of 25% albumin); 2)
                  add the appropriate volume of albumin to the IV bag and gently rotate; 3) add the albumin to IV bag and gently rotate to mix;
                  4) withdraw and discard a volume of the 0.1% albumin in NS injection from the IV bag equal to the volume of laronidase
                  concentrate to be added; 5) slowly withdraw the required amount of laronidase from vials (avoid excessive agitation), then
                  slowly add laronidase to the IV solution. Use immediately.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Infuse initially at 10 mcg/kg/h; may increase q15min during first h, as tolerated, to a max rate of 200 mcg/kg/hr. Maintain
                  max for remainder of the infusion (23 h).  Store at 2°8° C (36°46° F). Do not freeze or shake. Discard any unused drug. 
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> No compatibility data available. Do not recommend mixing or infusing with other drugs. 
               </p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Infusion reactions (flushing, fever, headache, rash), injection site pain, hypersensitivity reactions. <span class="typehead">CNS:</span> Hyperreflexia, paresthesias. <span class="typehead">CV:</span>  Chest pain, hypotension, edema. <span class="typehead">Hematologic:</span> Thrombocytopenia. <span class="typehead">Respiratory:</span> Upper respiratory tract infection. <span class="typehead">Skin:</span> Rash. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Half-Life:</span> 1.53.6 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for infusion-related reactions. Slow or stop infusion and notify physician for any of the following: cough, bronchospasm,
            dyspnea, urticaria, angioedema, pruritus, or other signs of hypersensitivity.
         </li>
<li>Lab tests: Periodic platelet count.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report promptly difficulty breathing, rash, or itching.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>